Revenue, Remaining Performance Obligation, Deferred Revenue
Schrodinger·Products & Services·3 segments·Rolls up to Revenue, Remaining Performance Obligation, Deferred Revenue
| Segment | Q1 '26 |
|---|---|
| Drug discovery | $95.17M |
| Software products and services | $66.96M |
| Contribution | $0 |
| Total | $162.13M |